Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 – ANRO

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].